High Growth Tech Stocks To Watch: Vertex And 2 Other Top Picks

In This Article:

As global markets rally on the back of anticipated interest rate cuts, small-cap stocks have been outperforming their larger counterparts, signaling a renewed investor confidence in growth sectors. In this favorable climate, identifying high-growth tech stocks with robust fundamentals and innovative edge becomes crucial for investors seeking to capitalize on market momentum.

Top 10 High Growth Tech Companies

Name

Revenue Growth

Earnings Growth

Growth Rating

TG Therapeutics

28.62%

43.05%

★★★★★★

Sarepta Therapeutics

24.22%

44.94%

★★★★★★

eWeLLLtd

26.52%

27.53%

★★★★★★

Medley

24.97%

30.50%

★★★★★★

Facilities by ADF

32.33%

94.46%

★★★★★★

G1 Therapeutics

27.57%

57.75%

★★★★★★

Clinuvel Pharmaceuticals

22.90%

28.13%

★★★★★★

KebNi

34.75%

86.11%

★★★★★★

Adveritas

66.47%

103.87%

★★★★★★

Adocia

59.08%

63.00%

★★★★★★

Click here to see the full list of 1275 stocks from our High Growth Tech and AI Stocks screener.

Let's review some notable picks from our screened stocks.

Vertex

Simply Wall St Growth Rating: ★★★★★☆

Overview: Vertex, Inc., along with its subsidiaries, offers enterprise tax technology solutions for retail trade, wholesale trade, and manufacturing industries both in the United States and internationally, with a market cap of $5.76 billion.

Operations: Vertex generates revenue primarily through its Software & Programming segment, which contributed $617.83 million. The company focuses on providing enterprise tax technology solutions across various industries both domestically and internationally.

Vertex's revenue surged to $161.1 million in Q2 2024, up from $139.7 million a year ago, with net income hitting $5.16 million compared to a prior loss of $6.9 million. The company forecasts annual revenue between $654 million and $660 million, driven by 28% growth in cloud services. R&D expenses reflect strategic investment at 12.2% of revenue, supporting innovations that could propel future earnings growth by an expected 38.9% annually over the next three years.

NasdaqGM:VERX Revenue and Expenses Breakdown as at Aug 2024

Zai Lab

Simply Wall St Growth Rating: ★★★★★☆

Overview: Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience, with a market cap of $1.77 billion.

Operations: Zai Lab Limited generates revenue primarily through its biotechnology segment, amounting to $322.71 million. The company focuses on developing and commercializing therapies for oncology, autoimmune disorders, infectious diseases, and neuroscience.